Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products

Nutrition Research

Volumn 34, Issue 9, 2014, Pages 807-813

  Maeda, Sayaka ^a   Matsui, Takanori ^a   Ojima, Ayako ^a   Takeuchi, Masayoshi ^b   Yamagishi, Sho ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

AGE; Diabetic retinopathy; Oxidative stress; Pericytes; RAGE; Sulforaphane

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; SULFORAPHANE; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; DNA; IMMUNOGLOBULIN RECEPTOR; ISOTHIOCYANIC ACID DERIVATIVE; PLANT EXTRACT; SULFORAFAN; SUPEROXIDE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; DNA SYNTHESIS; NONHUMAN; PERICYTE; PLEIOTROPY; PROTEIN EXPRESSION; RAGE GENE; REAL TIME POLYMERASE CHAIN REACTION; RETINA PERICYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BOVINE; BRASSICACEAE; CHEMISTRY; CYTOLOGY; DIABETIC RETINOPATHY; DRUG EFFECTS; GENETICS; INFLAMMATION; METABOLISM; RETINA;

BOVINAE;

ANIMALS; APOPTOSIS; BRASSICACEAE; CATTLE; CELLS, CULTURED; CHEMOKINE CCL2; DIABETIC RETINOPATHY; DNA; GLYCOSYLATION END PRODUCTS, ADVANCED; INFLAMMATION; ISOTHIOCYANATES; PERICYTES; PLANT EXTRACTS; RECEPTORS, IMMUNOLOGIC; RETINA; RNA, MESSENGER; SUPEROXIDES;

EID: 84921967720     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2014.08.010     Document Type: Article

References (39)

1. L'Esperance F.A., James W.A., Judson P.H. Ellenberg and Rifkin's Diabetes Mellitus, Theory and Practice 1990, 661-683. Elsevier, New York. H. Lifkin, D. Porte (Eds.).
2. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010, 61:34-39.
3. Frank R.N. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology 1991, 98:586-593.
4. Orlidge A., D'Amore P.A. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 1987, 105:1455-1462.
5. Yamagishi S., Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr Pharm Biotechnol 2011, 12:362-368.
6. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005, 11:2279-2299.
7. Rahbar S., Figarola J.L. Novel inhibitors of advanced glycation end products. Arch Biochem Biophys 2003, 419:63-79.
8. Barile G.R., Schmidt A.M. RAGE and its ligands in retinal disease. Curr Mol Med 2007, 7:758-765.
9. Zong H., Ward M., Stitt A.W. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep 2011, 11:244-252.
10. Stirban A., Gawlowski T., Roden M. Vascular effects of advanced glycation end products: clinical effects and molecular mechanisms. Mol Metab 2013, 3:94-108.
11. Yamagishi S., Amano S., Inagaki Y., Okamoto T., Koga K., Sasaki N., et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 2002, 296:877-882.
12. Yamagishi S., Inagaki Y., Amano S., Okamoto T., Takeuchi M., Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 2002, 290:973-978.
13. Inagaki Y., Yamagishi S., Okamoto T., Takeuchi M., Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003, 46:284-287.
14. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Ueda S., et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res 2008, 40:10-15.
15. Dong N., Li X., Xiao L., Yu W., Wang B., Chu L. Upregulation of retinal neuronal MCP-1 in the rodent model of diabetic retinopathy and its function in vitro. Invest Ophthalmol Vis Sci 2012, 53:7567-7775.
16. Ishibashi Y., Matsui T., Ueda S., Fukami K., Yamagishi S. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol 2014, 13:60.
17. Chen M., Curtis T.M., Stitt A.W. Advanced glycation end products and diabetic retinopathy. Curr Med Chem 2013, 20:3234-3240.
18. Guerrero-Beltrán C.E., Calderón-Oliver M., Pedraza-Chaverri J., Chirino Y.I. Protective effect of sulforaphane against oxidative stress: recent advances. Exp Toxicol Pathol 2012, 64:503-508.
19. Kaminski B.M., Steinhilber D., Stein J.M., Ulrich S. Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. Curr Pharm Biotechnol 2012, 13:137-146.
20. Zheng H., Whitman S.A., Wu W., Wondrak G.T., Wong P.K., Fang D., et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011, 60:3055-3066.
21. Negi G., Kumar A., Sharma S.S. Nrf2 and NF-κB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes. Curr Neurovasc Res 2011, 84:294-304.
22. Sasaki N., Takeuchi M., Chowei H., Kikuchi S., Hayashi Y., Nakano N., et al. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett 2002, 326:117-120.
23. Capetandes A., Gerritsen M.E. Simplified methods for consistent and selective culture of bovine retinal endothelial cells and pericytes. Invest Ophthalmol Vis Sci 1990, 31:1738-1744.
24. Yamagishi S., Inagaki Y., Nakamura K., Abe R., Shimizu T., Yoshimura A., et al. Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004, 37:497-506.
25. Nakamura K., Yamagishi S., Matsui T., Yoshida T., Takenaka K., Jinnouchi Y., et al. Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 2007, 170:2159-2170.
26. Higashimoto Y., Yamagishi S., Nakamura K., Matsui T., Takeuchi M., Noguchi M., et al. In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes. Microvasc Res 2007, 74:65-69.
27. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
28. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
29. Hammes H.P., Lin J., Renner O., Shani M., Lundqvist A., Betsholtz C., et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002, 51:3107-3112.
30. Yamagishi S., Amano S., Inagaki Y., Okamoto T., Takeuchi M., Makita Z. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol Med 2002, 8:546-550.
31. Maeda S., Matsui T., Takeuchi M., Yoshida Y., Yamakawa R., Fukami K., et al. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res 2011, 63:241-248.
32. Stitt A.W., Li Y.M., Gardiner T.A., Bucala R., Archer D.B., Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997, 150:523-531.
33. Kim J., Kim C.S., Sohn E., Kim J.S. Elevated Nε-(carboxymethyl)lysine is associated with apoptosis of retinal pericytes in streptozotocin-induced diabetic rats. Ophthalmic Res 2011, 46:92-97.
34. Mamputu J.C., Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J Leukoc Biol 2004, 75:1062-1069.
35. Matsumoto Y., Takahashi M., Ogata M. Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. Jpn J Ophthalmol 2002, 46:406-412.
36. Miyamoto K., Khosrof S., Bursell S.E., Rohan R., Murata T., Clermont A.C., et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 1999, 96:10836-10841.
37. Hanlon N., Coldham N., Gielbert A., Sauer M.J., Ioannides C. Repeated intake of broccoli does not lead to higher plasma levels of sulforaphane in human volunteers. Cancer Lett 2009, 284:15-20.
38. Shapiro T.A., Fahey J.W., Wade K.L., Stephenson K.K., Talalay P. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiol Biomarkers Prev 1998, 7:1091-1100.
39. Takeuchi M., Makita Z., Bucala R., Suzuki T., Koike T., Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000, 6:114-125.